Cabaletta Bio price target raised to $17 from $15 at H.C. Wainwright

H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Cabaletta Bio to $17 from $15 and keeps a Buy rating on the shares. The company is on track to initiate a Phase 1/2 clinical trial including two separate parallel cohorts of six systemic lupus erythematosus patients with active lupus nephritis and six patients without renal involvement, the analyst tells investors in a research note.